header logo image


Page 1,423«..1020..1,4221,4231,4241,425..1,4301,440..»

Life created for first time from eggs made from skin cells

October 5th, 2012 10:27 am

London, October 5 (ANI): Using stem cells made from skin, a Japanese team has created healthy eggs that, once fertilised, grow into normal baby mice.

These babies later had their own babies, the BBC reported.

The team at Kyoto University used stem cells from two sources: those collected from an embryo and skin-like cells, which were reprogrammed, into becoming stem cells.

The first step was to turn the stem cells into early versions of eggs.

A "reconstituted ovary" was then built by surrounding the early eggs with other types of supporting cells that are normally found in an ovary. This was transplanted into female mice. Surrounding the eggs in this environment helped them to mature.

IVF techniques were used to collect the eggs, fertilise them with sperm from a male mouse and implant the fertilised egg into a surrogate mother.

"They develop to be healthy and fertile offspring," Dr Katsuhiko Hayashi, from Kyoto University, told the BBC.

Those babies then had babies of their own, whose "grandmother" was a cell in a laboratory dish.

If the same methods could be used in people then, it could help infertile couples have children and even allow women to overcome the menopause.

But experts say many scientific and ethical hurdles must be overcome before the technique could be adapted for people.

Read the original post:
Life created for first time from eggs made from skin cells

Read More...

Mouse stem cells yield viable eggs

October 5th, 2012 10:27 am

Experimental approach might provide insights to support human fertility

Web edition : Thursday, October 4th, 2012

Some baby mice born in Japan are living proof that mouse stem cells taken from embryos or created by reprogramming fetal tissue can be used to make viable egg cells.

Researchers had already created functional sperm from stem cells, and some groups have reported making eggs, or oocytes, but those had never been shown to produce offspring. Now, Mitinori Saitou of Kyoto University in Japan and colleagues have coaxed mouse stem cell to make eggs that produce normal, fertile offspring, the researchers report online October 4 in Science.

This is really pioneering research, says Charles Easley, a reproductive stem cell biologist at Emory University School of Medicine in Atlanta.

The researchers have gone a step beyond making cells that merely look like eggs in a lab dish. This paper produces something that looks like oocytes, smells like oocytes and tastes like oocytes in a way no one has done before, says David Albertini, a reproductive scientist at the University of Kansas Medical Center in Kansas City.

While the evidence that the Japanese researchers have transformed mouse stem cells into functional female gametes is compelling, Albertini doesnt think the feat will be repeated with human stem cells because they are far less flexible than their mouse counterparts. The new technology might provide a way to test the effect that chemicals in the environment may have on fertility and give scientists new information about how eggs age, possibly leading to fertility-extending treatments, he says.

In the new study, Saitou and colleagues started with stem cells from very early mouse embryos as well as stem cells reprogrammed from fetal cells, known as induced pluripotent stem cells. Saitous team manipulated the activity of a few genes in the stem cells to turn them into cells that resemble precursors of gametes, as eggs and sperm are sometimes known.

These primordial germ celllike cells, as they are called, were mixed with support cells from an embryonic ovary and then transplanted into adult mice. Once the precursor cells had developed into oocytes, the researchers pulled them out and fertilized them in the lab before implanting the resulting embryos in female mice.

The oocytes made from either type of stem cell produced mouse pups 3.9 percent of the time. That rate is lower than for primordial germ cells taken directly from mouse embryos, which the researchers found produced pups 17.3 percent of the time. Oocytes taken from the ovaries of 3-week-old mice generated offspring 12.7 percent of the time. Female pups resulting from stem cellderived eggs grew up to become fertile adults, the researchers report.

View original post here:
Mouse stem cells yield viable eggs

Read More...

Mouse stem cells used to produce eggs, Japanese scientists say

October 5th, 2012 10:27 am

Reaching a long-sought milestone, Japanese researchers have demonstrated in mice that eggs and sperm can be grown from stem cells and combined to produce healthy offspring, pointing to new treatments for infertility.

If the achievement can be repeated in humans and experts said they are optimistic that such efforts will ultimately succeed the technique could make it easier for women in their 30s or 40s to become mothers. It could also help men and women whose reproductive organs have been damaged by cancer treatments or other causes.

About one in 10 American women of childbearing age have trouble becoming or staying pregnant, and more than one-third of infertile couples must contend with a medical problem related to the prospective father, according to the national Centers for Disease Control and Prevention in Atlanta.

Using current technology, only about one-third of attempts at assisted reproduction result in live births, CDC data show. Scientists, doctors and patients would like to boost that percentage.

"These studies provide that next level of evidence that in the future fertility could be managed with stem cell intervention," said Teresa Woodruff, chief of fertility preservation at Northwestern University Feinberg School of Medicine.

The prospect of using stem cells to grow new eggs is particularly tantalizing, since women are born with a set number and don't make more once they are gone. In a sense, the therapy would allow them to turn back their biological clocks, said Stanford stem cell researcher Renee A. Reijo Pera, who studies reproduction.

"This is a get-them-back strategy," she said.

Dr. Mitinori Saitou and colleagues at Kyoto University detailed how they generated the functional mouse eggs in a report published online Thursday by the journal Science. Last year, the researchers reported in the journal Cell that they had done the same thing with mouse sperm.

In both cases, the team started with embryonic stem cells, which have the potential to develop into all of the different types of cells in the body.

The scientists exposed the embryonic stem cells to stimuli that coaxed them to become egg and sperm precursors.

Follow this link:
Mouse stem cells used to produce eggs, Japanese scientists say

Read More...

Mouse stem cells lay eggs

October 5th, 2012 10:27 am

Mouse pups created using lab-made eggs went on to be fully fertile themselves.

Courtesy of Katsuhiko Hayashi

Japanese researchers have coaxed mouse stem cells into becoming viable eggs that produce healthy offspring1. The work provides a powerful tool to study basic elements of mammalian development and infertility that have long been shrouded in mystery.

People have been trying to make sex cells from embryonic stem cells and from pluripotent cells for years, says Evelyn Telfer, a reproductive biologist at the University of Edinburgh, UK. Theyve done it and theyve done it really well.

Stem-cell scientists have derived many types of cells from stem-cell precursors, but have struggled with sex cells. These cells have significantly more complex developmental programmes, in part because of the difference in the way they divide. Most cells in the body undergo mitosis, in which both sets of chromosomes are copied, but sex cells are produced by meiosis, which results in cells containing a single copy of each chromosome.

Last year, the same team from Mitinori Saitous lab at Kyoto University in Japan successfully used mouse stem cells to make functional sperm2. Whereas sperm cells are some of the simpler cells in the body, oocytes are much more complex.

It was always believed that making sperm was probably easier, says Davor Solter, a developmental biologist at the Institute of Medical Biology in Singapore, who was not involved with the study. The oocyte is the thing which makes the whole of development possible.

In the latest study, published today in Science, Saitou and his colleagues started with two cell types: mouse embryonic stem cells and induced pluripotent stem cells, which can be derived from adult cells. Just as in the earlier sperm study, they used a cocktail of signalling molecules to transform the stem cells first into epiblast cells and then into primordial germ cells (PGCs), both egg precursors. Whereas male PGCs could be injected directly into infertile male mice to mature into sperm, the female version required further coddling.

The researchers isolated embryonic ovary tissue that did not contain sex cells and then added their lab-made PGCs to the dish. The mixture spontaneously formed ovary-like structures, which they transplanted into female mice. After four weeks, the stem-cell-derived PGCs had matured into oocytes. The team fertilized them and transplanted the embryos into foster mothers. The offspring that were produced grew up to be fertile themselves.

PGCs are scarce and difficult to isolate from mice, so researchers know little about their regulation, says Saitou. As PGCs develop into sperm or egg cells, certain genes are silenced in a process called genomic imprinting. Although this is crucial for development, little is known about how it starts or how genes are selected for silencing.

View post:
Mouse stem cells lay eggs

Read More...

Skin cells become 'grandparents'

October 5th, 2012 10:27 am

4 October 2012 Last updated at 18:31 ET By James Gallagher Health and science reporter, BBC News

Stem cells made from skin have become "grandparents" after generations of life were created in experiments by scientists in Japan.

The cells were used to create eggs, which were fertilised to produce baby mice. These later had their own babies.

If the technique could be adapted for people, it could help infertile couples have children and even allow women to overcome the menopause.

But experts say many scientific and ethical hurdles must be overcome.

Stem cells are able to become any other type of cell in the body from blood to bone, nerves to skin.

Last year the team at Kyoto University managed to make viable sperm from stem cells. Now they have performed a similar feat with eggs.

They used stem cells from two sources: those collected from an embryo and skin-like cells which were reprogrammed into becoming stem cells.

I just thought wow! The science is quite brilliant

The first step, reported in the journal Science, was to turn the stem cells into early versions of eggs.

Visit link:
Skin cells become 'grandparents'

Read More...

Stem Cell Transplant May Spur Heart Disease Risk: Study

October 5th, 2012 10:20 am

WEDNESDAY, Oct. 3 (HealthDay News) -- People who undergo the transplantation of stem cells taken from bone marrow, circulating blood or umbilical cord blood are more likely to develop risk factors for heart disease, such as high blood pressure, diabetes and high cholesterol, a new study contends.

Researchers from the American Society of Hematology noted that patients who were treated with chemotherapy or radiation before such a transplant -- called a "hematopoietic cell transplant," or HCT -- had a significantly higher risk for heart disease later in life.

"While we know that heart disease is a real concern for long-term HCT survivors, small sample sizes and a lack of long-term follow-up in previous studies have only allowed us to look at a small piece of the puzzle of how this chronic condition develops in these patients," the study's first author, Dr. Saro Armenian, medical director of the Pediatric Survivorship Clinic in the Childhood Cancer Survivorship Program at City of Hope in Duarte, Calif., said in a society news release.

"Our study sought to better determine the specific factors before and after transplant that can lead to heart disease in a large group of transplant recipients," Armenian explained.

In conducting the study, the researchers examined the medical records of nearly 1,900 hematopoietic cell transplant recipients to identify factors that could affect their development of risk factors for heart disease. The transplants occurred between 1995 and 2004, and the patients survived for at least one year after the treatment.

The investigators considered the patients' exposure to chemotherapy or radiation before the transplant, the type of hematopoietic cell transplant and whether they were treated for a serious transplant complication known as graft-versus-host disease.

Using the U.S. National Health and Nutrition Examination Survey, the researchers also projected heart disease risk factor rates for the general population.

The study found that high blood pressure, diabetes and high cholesterol were more common among long-term survivors of the blood-forming stem cell transplants.

The risk for developing diabetes was 1.5 times higher for hematopoietic cell transplant survivors who underwent total body radiation. Their risk for high cholesterol was 1.4 times higher. The researchers noted this was true regardless of the type of blood-forming stem cell transplant the patient received.

Although it's unclear why total body radiation increased these patients' risk for diabetes and high cholesterol, previous studies have shown that abdominal radiation may contribute to insulin resistance and an increase in belly fat among cancer patients.

Follow this link:
Stem Cell Transplant May Spur Heart Disease Risk: Study

Read More...

Breast Enhancement with Stem Cells

October 5th, 2012 10:20 am

Whooping Cough Cases Decline Whooping Cough Cases Decline

In tonight's HealthierMe, some good news for Minnesota. State health officials say an outbreak of whooping cough appears to be slowing.

In tonight's HealthierMe, some good news for Minnesota. State health officials say an outbreak of whooping cough appears to be slowing.

In tonight's HealthierMe, the meningitis outbreak caused by a tainted batch of epidural steroid medication continues to expand. The CDC says there are now 35 meningitis cases in 6 states... 5 of which

In tonight's HealthierMe, the meningitis outbreak caused by a tainted batch of epidural steroid medication continues to expand. TheCDC says there are now 35 meningitis cases in 6 states... 5 of which have resulted in death.

In tonight's HealthierMe, promising news for women: a new breast enhancement procedure uses stem cells from fat and provides much more natural-looking results. Monica Robins sat down with one breast cancer

In tonight's HealthierMe, promising news for women: a new breast enhancement procedure uses stem cells from fat and provides much more natural-looking results. Monica Robins sat down with one breast cancer

In tonight's HealthierMe, the U.S. birth rate continues to fall -- a likely result of the weak economy. The centers for disease control and prevention reports births declined 1% in 2011. That's not as

In tonight's HealthierMe, theU.S. birth rate continues to fall -- a likely result of the weak economy. The centers for disease control and prevention reports births declined1% in 2011. That's not as steep as the 2% and 3% decreases seen in recent years, but the rate among Hispanic women fell the most last year -- 6%.Experts attribute the declines to a struggling economy, in which many people feel they cannot afford to have children.

Everyday American troops still stationed in Afghanistan and Iraq are putting themselves in harm's way, and that means many of them are suffering serious injuries on the battlefield. Doctors at the institute

See original here:
Breast Enhancement with Stem Cells

Read More...

To Combat Alzheimer's, Scientists Genetically Reprogram One Kind of Brain Cell Into Another

October 5th, 2012 10:19 am

A section of healthy brain tissues contrasted with brain tissue from someone who had advanced Alzheimer's disease. (Credit: National Institutes of Health, via Wikimedia Commons)

We all lose brain cells as we get older. In people with neurodegenerative diseases such as Alzheimers, Parkinsons and Huntingtons, neurons shrivel and die at alarming ratesperhaps three to four times faster than usual in Alzheimers, for example. Currently, no known drugs reliably halt or reverse such staggering cell death in people, although some drugs are thought to protect neurons from degradation.

An alternative to saving dying neuronsor perhaps a future supplemental therapyis creating brand new neurons. One way to accomplish this is transforming non-neuronal brain cells into functional neurons. On a cellular level, the brain is as diverse as a rainforest populated by many different species of trees. The human brain contains approximately 170 billion cells, 86 billion of which are neurons and 84 billion of which are glial cellsnon-firing cells that assist neurons in various ways. Star-shaped cells known as astrocytes are perhaps the best-studied of the many various glial cells and researchers have had some success converting astroyctes into neurons. Many of these studies, however, have used cells from very young rodent brains.

A study published this week suggests that its possible to turn at least one class of adult human brain cells known as pericytes into functional neurons. The fact that pericytes help defend and heal the brainand may retain some of the plasticity of stem cellsmakes them all the more appealing as candidate replacements for damaged and dying neurons.

Benedikt Berninger of Ludwig-Maximilians University Munich and his colleagues began their research project with the intent to study astrocytes, just as they have done many times before. They acquired 30 samples of brain tissue from people who were undergoing surgery for disorders such as epilepsy. Sometimes, in order to remove or treat a damaged or malfunctioning brain region, neurosurgeons cannot avoid slicing through healthy brain tissue. Surgeons routinely provide sections of such healthy tissue to researchers studying the brain.

In the lab, Berninger and his teammates grew cultures of brain cells from the tissue samples and searched for astrocytes nestled among the tiny neural gardens. As it turned out, the cultures Berninger and his colleagues grew were mostly devoid of astrocytes. Instead, their Petri dish gardens were rife with pericytesnon-neuronal brain cells that wrap themselves around the brains delicate blood vessels, regulate blood flow to neurons and help maintain the blood-brain barrier, which protects neurons from bacteria and other pathogens. Pericytes are also known to proliferate in response to injury. Researchers recently showed, for example, that pericytes are essential for the formation of scar tissue in an injured spinal cord. Some evidence even suggests that certain kinds of pericytes boast the same flexibility as mesenchymal stem cellsthey can turn into bone cells, fat cells or cartilage cells. Perhaps, Berninger and his colleagues reasoned, the plasticity of pericytescoupled with their role in healingmight make them especially useful in future treatments for neurodegenerative diseases. So they decided to try changing pericytes into neurons by reprogramming their genomes.

An astrocyte stained with green fluorescent proteins (Credit: Dantecat, via Wikimedia Commons)

Using viruses, Berninger and his team infected the pericytes in their cultures with two transcription factorsproteins that alter gene expression by binding to segments of DNA and making certain genes more or less accessible to other cellular machinery. One of the transcription factors, Mash1, is known to guide the development of the nervous system. We all begin life as a hollow ball of embryonic stem cells that eventually become the many different kinds of cells in the human body. All somatic cells in your body have the same DNA, but distinct types of cells express very different sets of genesjust as different piano songs are unique combinations of notes played on the exact same set of keys. MASH 1 is like a tiny composer inside embryonic stem cells, making sure they turn on the right combination of genes to become neurons. The second transcription factor Berninger and his colleagues introduced into pericytes was Sox2, which is highly active in stem cells and thought to make DNA more amenable to manipulation by loosening the chemical bonds between DNA and the protein scaffolding that keeps it tightly wound in a bundle called chromatin.

The scientists successfully converted between 10 and 30 percent of the pericytes in various cultures into neurons; the overall success rate was 19 percent. Out of 17 successfully converted neurons selected for further testing, 12 generated electrical impulses. Berninger and his colleagues replicated these results with brain cells from adult mice. The results appear in Cell Stem Cell.

Treating neurodegenerative diseases by genetically reprogramming brain cells is a potential avenue for therapy that researchers have just started to navigateand they will have to scale plenty of hurdles along the way. Scientists must ensure that the viruses they use to ferry genes into neurons are harmless. And they would likely have to perform risky invasive surgery to get the viruses into exactly the right region of the brain. In recent years, however, gene therapy has safely restored vision to the blind. Not only do studies like Berningers suggest that gene therapy for the brain has similar potential, they also confirm that the fates of some adult cells are not written in stonerather, they are written in highly editable DNA.

See more here:
To Combat Alzheimer's, Scientists Genetically Reprogram One Kind of Brain Cell Into Another

Read More...

Snake Venom Could Relieve Pain; Baby Mice Birthed From Stem Cells

October 5th, 2012 10:19 am

Discovered: A whole new type of lab mouse; black mamba venom dulls pain better than morphine; drilling deep into the Earth; microbial diversity turned into jazz.

RELATED: Appeals Court Rules Against Ban on Federal Stem Cell Funding

A palliative use for snake venom. Probably very few people would willfully put snake venom in their bodies. But if they knew that it would relieve terrible pain without any nasty side-effects, perhaps they'd be more willing to ingest black mamba venom. Researchers in France have isolated mambalgins in the snake's venom which can block pain in sensory nerves and inhibit the passage of pain signals through the central nervous system. Though their painkilling effects are on par with morphine, these mambalgins are "powerful, naturally occurring, analgesic peptides of potential therapeutic value" that "do not produce motor dysfunction, apathy, flaccid paralysis, convulsions or death upon central injections." That means that they could greatly alleviate pain without causingmany of the nasty side effects involved in taking other painkillers. [Ars Technica]

RELATED: First Fully Lab-Grown Organ Successfully Transplanted

Baby mice born from stem cells. Giving a whole new meaning to the term "lab mouse," scientists in Japan have fostered baby mice into being through stem cells. Kyoto University's Mitinori Saitouand colleagueswere able to grow "reconstituted ovaries" from the stem cells. They then fertilized the eggs using in vitro technology. The baby mice that emerged were healthy and fertile, making this the first time scientists have successfully grown baby mice through stem cell research. "Our system serves as a robust foundation to investigate and further reconstitute female germline development in vitro, not only in mice, but also in other mammals, including humans," the researchers write.[The Guardian]

RELATED: Stem Cell Breakthrough Offers Hope for Endangered Animals

Microbial jazz. The complexity of microbial life presents a unique challenge to microbiologists: how to organize and make sense of it all. Argonne National Laboratory researcher Peter Larsen came up with one interesting solution by using music to map out patterns in microbial diversity. He took data from the English Channel project, a long-running effort to collect informationon microbes living in the Western English Channel and then matched certain variables (daylight, temperature,phosphorouslevels, etc.) with chords. Concentrations of the microbes determined which scales come into play. "The same population would sound different in the key of sunlight, says Larsen, than in the key of nitrogen." Jazz is the most suitable genre, Larsen found, because it best mimics the spontaneity he observes when looking at microbes under the microscope. Listen to microbial diversity swing below. [Tooth & Claw]

RELATED: Oklahoma Legislator Doesn't Really Think We're Eating Fetuses

RELATED: An Alternative to Embryonic Stem Cells; Some Fish Can Handle Climate Change

Journey to the center of the Earth. OK, maybe not all the way down to the inner core, but scientists are planning to drill quite deep into the Earth in an effort by the internationalIntegrated Ocean Drilling Program(IODP). What we know so far about the layers of the Earth come from computer simulations, mostly, but IODP plans to change that by drilling 3.7 miles into the Earth beneath the Pacific Ocean. There, the drill will retrieve the first-ever samples to be collected from within the Earth's mantle. One of the project's leaders, the University of Southampton in England's Damon Teagle, says this will be "the most challenging endeavor in the history of earth science." Japanese scientists currently hold the tunneling depth record, having drilled 7,000 feet below the seafloor last month.We currently know more about the surface of Mars than what lies just beneath the Earth's crust, and this project hopes to fix that irony. [Smithsonian]

Read more from the original source:
Snake Venom Could Relieve Pain; Baby Mice Birthed From Stem Cells

Read More...

'Humanized' mice may enable discovery of better medicines for rheumatoid arthritis

October 5th, 2012 10:18 am

Washington, October 5 (ANI): By developing the first animal model that duplicates the human response in rheumatoid arthritis (RA), researchers at Northwestern University Feinberg School of Medicine have made a breakthrough in their search for better therapies to combat the disease.

This is the first time human stem cells have been transplanted into mice in order to find RA treatments, said corresponding and senior author Harris Perlman, associate professor of rheumatology at Feinberg.

"We believe this will improve drug discovery because the reactions we observed were authentic human reactions," he stated.

Until now, scientists have relied on the common scientific method of using specially bred mice to find drugs to control RA. However, human and mouse immune systems differ dramatically, so studying RA in these mice does not give an accurate representation of how the disease functions in humans. In some cases, RA drugs that seemed promising based on results in mice failed in human clinical trials.

Mice implanted with human stem cells have been used before mainly to study infectious disease.

The Northwestern team injected day-old mice with human stem cells from umbilical cord blood, including white blood cells, which regulate immunity. Then, RA was introduced in the mice and suppressed with Enbrel, a common first-line drug for joint inflammation in humans. This offered evidence that their immune systems were indeed replicating human defences.

Scientists seek mouse models that mimic RA in humans in order to learn how the complex disease operates. In the last decade, researchers and physicians have found many subtypes of RA that originate on the molecular level and are each produced by different pathways in the body.

A debilitating disease, rheumatoid arthritis is a chronic autoimmune disorder characterized by persistent inflammation around joint areas, predominantly in the wrist and fingers. The disease causes pain, swelling, stiffness and loss of function and can result in tissue destruction. Approximately 1.3 million people have the disease.

Onset of RA usually begins between ages 25 to 55, but recent studies reveal that the disease actually begins several years before symptoms appear. This has broadened the focus to create drugs that prevent RA or at least enable early diagnosis instead of trying to reduce symptoms once it is further along and difficult to control.

This is the second mouse model Perlman has developed to help discover better rheumatoid arthritis therapies. Earlier this year, he introduced a mouse model that develops RA and is predisposed to atherosclerosis, or hardening of the arteries, a common RA complication in humans.

Original post:
'Humanized' mice may enable discovery of better medicines for rheumatoid arthritis

Read More...

Bernard Siegel to Deliver Keynote Addresses at Midwest Conference on Stem Cell Biology and Therapy and BioFlorida …

October 4th, 2012 7:22 pm

PALM BEACH, Fla.--(BUSINESS WIRE)--

Genetics Policy Institute (GPI) announced today that Bernard Siegel, Executive Director of GPI, will make two keynote presentations this month at regional conferences: Midwest Conference on Stem Cell Biology and Therapy October 5-7 in Rochester, Michigan and BioFlorida Conference 2012 October 7-9 in Miami, Florida.

Siegel will present a keynote address titled The Power of Advocacy at the Midwest Conference on Stem Cell Biology and Therapy. The Genetics Policy Institute joined with the Oakland University William Beaumont Institute for Stem Cell and Regenerative Medicine (ISCRM) as a collaborating partner for the event. Researchers from hospitals, medical organizations, academic institutions and the business community throughout the Midwest will discuss not only the latest advances in this rapidly expanding field of medical science, but the ethical and moral issues that surround it.

"I am pleased to participate in these important conferences, which showcase the latest scientific developments in their respective regions and beyond. ISCRM and the World Stem Cell Summit have a strong connection, as the Institute was officially launched at our 2010 Summit in Detroit, said Bernard Siegel, GPI's Executive Director and founder of the annual World Stem Cell Summit.

BioFloridas 15th annual Conference is the premier event for Floridas bioscience community. This years meeting will bring together more than 500 professionals from across Florida, the Southeast and the nation to discuss major trends and issues, including topics related to product development, scientific research, business development, financing and public policy.

Siegels keynote address at BioFlorida is titled: The Mandate to Deliver Cures: Aligning Patient Advocacy, Industry and Science. Former Governor Jeb Bush will deliver the second keynote at BioFloridas annual Conference.

The 2012 World Stem Cell Summit is in West Palm Beach, Florida this December, so we have been working closely with the biotechnology community here. I am delighted to partner with BioFlorida as they advance Floridas bioscience industry," said Siegel, who also serves on the Executive Committee of the Alliance for Regenerative Medicine and Board of the Coalition for Advancement of Medical Research. He serves as spokesperson for the Stem Cell Action Coalition.

ABOUT GPI:The Genetics Policy Institute (GPI) supports stem cell research to develop therapeutics and cures. GPI pursues its mission by honoring leadership through the Stem Cell Action Awards, producing the World Stem Cell Summit, publishing theWorld Stem Cell Report, organizing educational initiatives and fostering strategic collaborations. For more information, visitwww.genpol.org.

ABOUT THE WORLD STEM CELL SUMMIT:The 2012 World Stem Cell Summit is presented by GPI and is co-organized by the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine, Diabetes Research Institute, Beckman Research Institute at City of Hope, Karolinska Institute (home of the Nobel Prize in Physiology and Medicine), International Translational Regenerative Medicine Center (ITRC) and the Institute for Integrated Cell-Material Sciences (iCeMS) at Kyoto University. The Summit is the flagship meeting of the world stem cell community. The 2012 Summit will be held at the Palm Beach County Convention Center in West Palm Beach, Florida, December 3-5, 2012. For more information, visit http://www.worldstemcellsummit.com.

Go here to see the original:
Bernard Siegel to Deliver Keynote Addresses at Midwest Conference on Stem Cell Biology and Therapy and BioFlorida ...

Read More...

Pluristem unveils portable stem cells thawing device

October 4th, 2012 2:28 pm

Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) today announced that it has developed a portable instrument for thawing its placenta-based stems cell (PLX cells) on-site before they are administered to patients.

Pluristem will ship its off-the-shelf PLX cell therapy product candidates, which will be stored in multiple dose vials that require thawing prior to use. The vial will be placed into the proprietary thawing device and PLX cells will be ready for a convenient intramuscular injection. The company said that if the trials of the instrument are successful, it will be used as the final step in bringing high quality, clinical grade PLX cell products to patients around the globe.

"Pluristem understands the importance of providing a standardized product with every dose of these living drug delivery devices," said Pluristem chairman and CEO Zami Aberman. "If we are successful, we want our PLX cell products, once developed, to be an easy-to-use therapy. This thawing device will give us better control of several variables in our clinical trials and in treating patients after our products have been approved assuming we are successful. This instrument is an additional step in our vision to bring PLX cells as first-line therapies for a variety of indications and to think about the cell delivery process all the way from mass manufacturing to the patient's bedside."

Pluristem's share price rose 4.3% on the TASE today to NIS 16.05, after the announcement, after rising 4.4% on Nasdaq yesterday to $4.07, giving a market cap of $193 million.

Published by Globes [online], Israel business news - http://www.globes-online.com - on October 4, 2012

Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Read the original here:
Pluristem unveils portable stem cells thawing device

Read More...

OncoMed Pharmaceuticals Advances Two Notch Pathway Product Candidates in Clinical Development

October 4th, 2012 2:28 pm

REDWOOD CITY, Calif.--(BUSINESS WIRE)--

OncoMed Pharmaceuticals, Inc., a clinical stage, research and discovery company developing novel therapeutics that target cancer stem cells, today announced clinical progress with two of its Notch pathway product candidates, resulting in $8 million in milestone payments from the companys strategic collaborator GlaxoSmithKline (GSK).

Anti-Notch2/3 (OMP-59R5)

OncoMed has initiated a Phase 1b/2 clinical trial in its anti-Notch2/3 antibody (OMP-59R5) program. In the Phase 1b/2 ALPINE trial (Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety), Anti-Notch2/3 is being tested in combination with gemcitabine in first-line advanced pancreatic cancer patients. Following a Phase 1b safety run-in, a randomized Phase 2 clinical trial will proceed in these patients to compare the efficacy of standard-of-care gemcitabine either with Anti-Notch2/3 or with placebo. The two primary endpoints of the Phase 2 part of the trial will be progression-free survival (PFS) in the Anti-Notch2/3 arm compared to a placebo arm in all patients, as well as in patients who have a particular biomarker. Key secondary and exploratory endpoints include overall survival, response rate, and safety, and these endpoints will be assessed in all patients, as well as in the biomarker positive subset of patients.

Dr. Lon Smith, from the South Texas Accelerated Research Therapeutics (START) Center for Cancer Care, who treated the first patient dosed in the ALPINE study, noted, This is an exciting new clinical trial with a novel anti-cancer treatment that we hope will have a big impact for patients with pancreatic cancer. The fact that the trial also includes a predictive biomarker to potentially identify patients who might gain greater clinical benefit from Anti-Notch2/3 is also a new and exciting direction in the experimental treatment of patients with pancreatic cancer.

Anti-Notch1 (OMP-52M51)

An Investigational New Drug (IND) application filed by OncoMed has been accepted by the FDA, thereby allowing OncoMed to advance its anti-Notch1 antibody (OMP-52M51) to clinical testing. OncoMed plans to initiate a single-agent, dose escalation and expansion Phase 1 clinical trial in hematologic cancers in 2012 and plans to file an additional IND application later in 2012 in solid tumors. The clinical trials will assess safety, pharmacokinetics, pharmacodynamics, and initial evidence of efficacy via a biomarker-based patient selection approach.

The OMP-59R5 Phase 1b/2 clinical program is our first Phase 2 trial and represents a significant advancement in the companys pipeline of anti-cancer stem cell therapies, said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals. In addition, the acceptance from the FDA to begin clinical testing for OMP-52M51 represents the fifth product candidate from our R&D platform to be cleared to enter clinical testing. For both programs, we have developed comprehensive biomarker strategies to facilitate efficient development in patients we believe will be most likely to benefit from targeted Notch pathway signaling blockade, added Hastings.

OMP-59R5 and OMP-52M51 are part of OncoMeds collaboration with GlaxoSmithKline. In December 2007, OncoMed and GSK entered into a broad strategic alliance to discover and develop novel product candidates targeting cancer stem cells via Notch pathway signaling modulation. GSK retains an option through the end of certain Phase 2 clinical trials to obtain an exclusive license to OMP-59R5. GSK also retains an option through the end of certain Phase 1 or certain Phase 2 clinical trials to obtain an exclusive license to OMP-52M51.

About Cancer Stem Cells

View post:
OncoMed Pharmaceuticals Advances Two Notch Pathway Product Candidates in Clinical Development

Read More...

StemCells, Inc. Announces First Transplant of Neural Stem Cells Into Patient in Clinical Trial for Dry Age-Related …

October 4th, 2012 2:28 pm

NEWARK, Calif., Oct. 4, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that the first patient in its Phase I/II clinical trial in dry age-related macular degeneration (AMD) has been enrolled and transplanted. The trial is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) as a treatment for dry AMD, and the patient was transplanted with the cells yesterday at the Retina Foundation of the Southwest (RFSW) in Dallas, Texas, one of the leading independent vision research centers in the United States. AMD afflicts approximately 30 million people worldwide and is the leading cause of vision loss and blindness in people over 55 years of age.

"This trial signifies an exciting extension of our on-going clinical research with neural stem cells from disorders of the brain and spinal cord to now include the eye," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Studies in the relevant animal model demonstrate that the Company's neural stem cells preserve vision in animals that would otherwise go blind and support the therapeutic potential of the cells to halt retinal degeneration. Unlike others in the field, we are looking to intervene early in the course of the disease with the goal of preserving visual function before it is lost."

David G. Birch, Ph.D., Chief Scientific and Executive Officer of the RFSW and Director of the Rose-Silverthorne Retinal Degenerations Laboratory and principal investigator of the study, added, "We are excited to be working with StemCells on this ground breaking clinical trial. There currently are no effective treatments for dry AMD, which is the most common form of the disease, and there is a clear need to explore novel therapeutic approaches."

In February 2012, the Company published preclinical data that demonstrated HuCNS-SC cells protect host photoreceptors and preserve vision in the Royal College of Surgeons (RCS) rat, a well-established animal model of retinal disease which has been used extensively to evaluate potential cell therapies. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed in the study. In humans, degeneration of the cone photoreceptors accounts for the unique pattern of vision loss in dry AMD. The data was published in the international peer-reviewed European Journal of Neuroscience.

About Age-Related Macular Degeneration

Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. AMD is a degenerative retinal disease that typically strikes adults in their 50s or early 60s, and progresses painlessly, gradually destroying central vision. According to the RFSW website, there are approximately 1.75 million Americans age 40 years and older with some form of age-related macular degeneration, and the disease continues to be the number one cause of irreversible vision loss among senior citizens in the United States with more than seven million at risk of developing AMD.

About the Trial

The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina in the most affected eye. Patients' vision will be evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations will be performed at predetermined intervals over a one-year period to assess safety and signs of visual benefit. Patients will then be followed for an additional four years in a separate observational study. Patients interested in participating in the clinical trial should contact the site at (214) 363-3911.

About HuCNS-SC Cells

StemCells' proprietary product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company's preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system (CNS) with no sign of tumor formation or adverse effects. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, there is the possibility of a durable clinical effect following a single transplantation. StemCells believes that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the CNS, and to date has demonstrated human safety data from completed and ongoing clinical studies.

Read more from the original source:
StemCells, Inc. Announces First Transplant of Neural Stem Cells Into Patient in Clinical Trial for Dry Age-Related ...

Read More...

Bernard Siegel to Deliver Keynote Addresses at Midwest Conference on Stem Cell Biology and Therapy and BioFlorida …

October 4th, 2012 2:23 pm

PALM BEACH, Fla.--(BUSINESS WIRE)--

Genetics Policy Institute (GPI) announced today that Bernard Siegel, Executive Director of GPI, will make two keynote presentations this month at regional conferences: Midwest Conference on Stem Cell Biology and Therapy October 5-7 in Rochester, Michigan and BioFlorida Conference 2012 October 7-9 in Miami, Florida.

Siegel will present a keynote address titled The Power of Advocacy at the Midwest Conference on Stem Cell Biology and Therapy. The Genetics Policy Institute joined with the Oakland University William Beaumont Institute for Stem Cell and Regenerative Medicine (ISCRM) as a collaborating partner for the event. Researchers from hospitals, medical organizations, academic institutions and the business community throughout the Midwest will discuss not only the latest advances in this rapidly expanding field of medical science, but the ethical and moral issues that surround it.

"I am pleased to participate in these important conferences, which showcase the latest scientific developments in their respective regions and beyond. ISCRM and the World Stem Cell Summit have a strong connection, as the Institute was officially launched at our 2010 Summit in Detroit, said Bernard Siegel, GPI's Executive Director and founder of the annual World Stem Cell Summit.

BioFloridas 15th annual Conference is the premier event for Floridas bioscience community. This years meeting will bring together more than 500 professionals from across Florida, the Southeast and the nation to discuss major trends and issues, including topics related to product development, scientific research, business development, financing and public policy.

Siegels keynote address at BioFlorida is titled: The Mandate to Deliver Cures: Aligning Patient Advocacy, Industry and Science. Former Governor Jeb Bush will deliver the second keynote at BioFloridas annual Conference.

The 2012 World Stem Cell Summit is in West Palm Beach, Florida this December, so we have been working closely with the biotechnology community here. I am delighted to partner with BioFlorida as they advance Floridas bioscience industry," said Siegel, who also serves on the Executive Committee of the Alliance for Regenerative Medicine and Board of the Coalition for Advancement of Medical Research. He serves as spokesperson for the Stem Cell Action Coalition.

ABOUT GPI:The Genetics Policy Institute (GPI) supports stem cell research to develop therapeutics and cures. GPI pursues its mission by honoring leadership through the Stem Cell Action Awards, producing the World Stem Cell Summit, publishing theWorld Stem Cell Report, organizing educational initiatives and fostering strategic collaborations. For more information, visitwww.genpol.org.

ABOUT THE WORLD STEM CELL SUMMIT:The 2012 World Stem Cell Summit is presented by GPI and is co-organized by the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine, Diabetes Research Institute, Beckman Research Institute at City of Hope, Karolinska Institute (home of the Nobel Prize in Physiology and Medicine), International Translational Regenerative Medicine Center (ITRC) and the Institute for Integrated Cell-Material Sciences (iCeMS) at Kyoto University. The Summit is the flagship meeting of the world stem cell community. The 2012 Summit will be held at the Palm Beach County Convention Center in West Palm Beach, Florida, December 3-5, 2012. For more information, visit http://www.worldstemcellsummit.com.

Link:
Bernard Siegel to Deliver Keynote Addresses at Midwest Conference on Stem Cell Biology and Therapy and BioFlorida ...

Read More...

ORF Genetics to Offer endotoxin- and Animal-free FGFb and mLIF for Stem Cell Research

October 4th, 2012 2:21 pm

REYKJAVIK, Iceland, October 4, 2012 /PRNewswire/ --

ORF Genetics announced today that the company has added endotoxin- and animal-free human Fibroblast Growth Factor Basic (FGF basic) and mouse Leukemia Inhibitory Factor (mouse LIF) to its portfolio of growth factors for stem cell research.

Most growth factors applied in stem cell research today are made in E. coli bacteria, which produce endotoxins that can have adverse effect on stem cell cultures. Other manufacturers of growth factors have various methods to remove these endotoxins, but traces inevitably remain, which can lead to increased death rate of cells and other suboptimal effects in cell cultures. Other growth factors on the market today are made by animal cells. However, most stem cell researchers prefer to use growth factors of non-animal origin to exclude risks of viral contamination and the inclusion of growth factor homologs.

This has led to a market demand for alternative sources of animal-free growth factors, void of endotoxins. ORF Genetics' unique growth factors are produced in the seeds of the barley plant, which does not produce any endotoxins or other substances toxic to mammalian cells.

FGF basic and mouse LIF are key growth factors for the cultivation of their respective stem cells, i.e. FGF basic for human stem cells and mouse LIF for mouse stem cells. Each protein is used to expand the stem cells' populations before researchers make them differentiate into various cell types, such as heart, liver or neural cells.

"ORF Genetics has built a reputation for offering the first plant-made, endotoxin-free and animal-free growth factor portfolio for stem cell researchers. As we are producing these growth factors in our novel plant expression system ORFEUS, we are very happy to be able to offer these high quality growth factors at more efficient prices than market leaders," said Bjrn rvar, CEO of ORF Genetics.

ORF Genetics is a world leader of plant made growth factors and offers a portfolio of endotoxin- and animal-free growth factors for human stem cell research. The company's production takes place in a biorisk-free production system in barley, bypassing conventional bacteria and animal cell production systems. The cultivation of barley takes place in greenhouses in inert volcanic pumice, using renewable geothermal energy.

For more information please contact:

Dr. Hakon Birgisson, Director of Global Market Development Tel: +354-821-1585 email:hakon.birgisson@orfgenetics.com

Original post:
ORF Genetics to Offer endotoxin- and Animal-free FGFb and mLIF for Stem Cell Research

Read More...

'Humanized' mice advance study of rheumatoid arthritis

October 4th, 2012 2:20 pm

Public release date: 3-Oct-2012 [ | E-mail | Share ]

Contact: Marla Paul Marla-Paul@northwestern.edu 312-503-8928 Northwestern University

Researchers at Northwestern University Feinberg School of Medicine have developed the first animal model that duplicates the human response in rheumatoid arthritis (RA), an important step that may enable scientists to discover better medicines to treat the disease.

Corresponding and senior author Harris Perlman, associate professor of rheumatology at Feinberg, introduced his team's new prototype mouse model in a recent online issue of the Journal of Translational Medicine.

"This is the first time human stem cells have been transplanted into mice in order to find RA treatments," Perlman said. "We believe this will improve drug discovery because the reactions we observed were authentic human reactions."

Until now, scientists have relied on the common scientific method of using specially bred mice to find drugs to control RA. However, human and mouse immune systems differ dramatically, so studying RA in these mice does not give an accurate representation of how the disease functions in humans. In some cases, RA drugs that seemed promising based on results in mice failed in human clinical trials.

Mice implanted with human stem cells have been used before mainly to study infectious disease.

The Northwestern team injected day-old mice with human stem cells from umbilical cord blood, including white blood cells, which regulate immunity. Then, RA was introduced in the mice and suppressed with Enbrel, a common first-line drug for joint inflammation in humans. This offered evidence that their immune systems were indeed replicating human defenses.

Scientists seek mouse models that mimic RA in humans in order to learn how the complex disease operates. In the last decade, researchers and physicians have found many subtypes of RA that originate on the molecular level and are each produced by different pathways in the body.

A debilitating disease, rheumatoid arthritis is a chronic autoimmune disorder characterized by persistent inflammation around joint areas, predominantly in the wrist and fingers. The disease causes pain, swelling, stiffness and loss of function and can result in tissue destruction. Approximately 1.3 million people have the disease.

See the original post:
'Humanized' mice advance study of rheumatoid arthritis

Read More...

UCI stem cell center awes students

October 4th, 2012 12:30 am

IRVINE High school sophomore Derek Le said he's always been interested in science. But it wasn't until he saw how researchers could use stem cells to repair tissue damaged by heart attacks that Le thought science could be his future career.

"Wow, this is so amazing," said Le, a student from Westminster High. "They can create cells to fix people's hearts. I think I want to do something like this."

Emily Nordhoff, Junior Research Specialist is harnessed in a body weight support system that is used to measure walking patterns. More than 250 high school students took a tour of UC Irvine's Stem Cell program to learn about stem cell research.

CHRISTINE COTTER, FOR THE REGISTER

ADVERTISEMENT

The center was established at UC Irvine in 2010 with help of a $10 million endowment from PIMCO founder and his wife.

Mission

The center's goals include training new researchers, providing state-of-the-art tissue culture labs and equipment, and testing new technologies and products related to stem cells research.

Accomplishments

Recent accomplishments include: securing first federally approved embryonic stem cell based therapy to go to clinical trial; developing of bone marrow stem cell treatment for stroke patients; and development of treatments for retinitis pigmentosa and macular degeneration.

Link:
UCI stem cell center awes students

Read More...

Verastem to Present at BIO Investor Forum and Participate in Cancer Stem Cell Panel

October 4th, 2012 12:30 am

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will present at the BIO Investor Forum on October 9, 2012, at the Palace Hotel in San Francisco, CA.

The company presentation is at 8:30 am PT in the Presidio room and Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research, will participate on a cancer stem cell panel from 10:30-11:25 am PT in the Twin Peaks room.

The panel will bring together scientific experts who are at the forefront of developing novel medicines targeting cancer stem cells. Dr. Pachter will discuss the potential of this approach to create durable clinical responses for patients with cancers that are typically refractory to conventional treatments. Verastem is translating basic science into clinical products based on the seminal publications in Cell and PNAS by Robert Weinberg, Ph.D., Verastem co-founder and chair of the Scientific Advisory Board.

A webcast of the company presentation can be accessed by visiting the investors section of the Companys website at http://www.verastem.com. A replay of the webcast will be archived on the Verastem website for two weeks following the presentation date.

About Verastem, Inc.

Verastem, Inc. (VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: focal adhesion kinase (FAK), PI3K/mTOR and Wnt. For more information, please visit http://www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Companys views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Read the original:
Verastem to Present at BIO Investor Forum and Participate in Cancer Stem Cell Panel

Read More...

Study Shows Epigenetics Of Adult Stem Cells Influences Organ Creation

October 4th, 2012 12:24 am

October 3, 2012

Alan McStravick for redOrbit.com Your Universe Online

Ask a handful of people about their thoughts and feelings on the use of stem cells for research and therapeutic means and you will find that they each have strong and varying positions on the topic. Outside the scientific community, however, little is known about this highly complex field of research.

The politicization of stem cell research accompanied the 1998 discovery that embryonic stem cells, the building blocks of organ, tissue, bone and brain cells, could be extracted for study and medical use. In 2001, with an order to limit the lines of stem cell research to those already in possession of the scientific community, President George W. Bush largely hampered the development of this field in the United States by limiting government funding for stem cell research. Adult stem cells, or somatic stem cells, were unaffected by this order, but the prevailing wisdom of the genetic community was that adult stem cells were not as dynamic and couldnt be used in the same way as their embryonic cousins.

With a report published Monday in the American Journal of Pathology, that truth no longer seems to be the case. A team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program in the Bellvitge Biomedical Research Institute (IDIBELL), was able to identify epigenetic changes that occur in the somatic stem cells to generate different body tissues.

The use of somatic or adult stem cells had been a regular occurrence since their discovery in the 1950s. It was then that researchers found that bone marrow contains two different kinds of stem cells. The first, called hematopoietic stem cells, form all the types of blood cells in the body. The second, known as bone marrow stromal stem cells, were discovered only a few years later and are effective in the generation of bone, cartilage, fat and fibrous connective tissues.

One thing that has been understood is that the genome of each cell in the human body is identical. This is true regardless of their appearance and function. It is for this reason that certain anomalies, such as cancer, are seemingly incomprehensible as they are unable to be explained by the genome of the host. To better understand such complex genetic deviations, something more is required.

Researchers in this current study offer an explanation via analogy. Epigenetics is defined as the inheritance of DNA activity that does not depend on the strict sequence of it. According to the team, if genetics is the alphabet, spelling would be the epigenetics, referring to chemical changes in our genetic material as well as the proteins that regulate and control their activity.

We now know that somatic stem cells have enormous potential to regenerate damaged organs. By investigating how to use them more effectively in different types of therapies, the research team postulates that it will become easier to steer clear of any sticky ethical complications that might arise from working with embryonic stem cells.

In this study, the team was able to isolate somatic stem cells from body fat, allowing them to transform them into muscle and bone cells. Through their study, they observed the resemblance of the cells created in the laboratory to those of the host individual. They were also able to determine that the cells were biologically secure enough that they might be implanted into waiting patients. Overall, the study was able to show that the epigenome of the cells obtained and maintained in culture closely resembled skeletal and muscle cells that are spontaneously present in nature, though not completely identical.

Read more:
Study Shows Epigenetics Of Adult Stem Cells Influences Organ Creation

Read More...

Page 1,423«..1020..1,4221,4231,4241,425..1,4301,440..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick